The Service of the Commission for the Protection of Competition received on behalf of Aenova Holding GmbH notification of the proposed concentration according to Section 13 of the Control of Concentrations between Enterprises Law (Number 22(I)/99), concerning the proposed acquisition of Haupt Pharma A.G., with its subsidiaries, excluding Haupt Pharma Latina S.r.l., Haupt Pharma Livron S.A.S. (France) and Haupt Pharma Inc. (U.S.A.).
Aenova Holding Gmbh is a development and production "CDMO" contract company active in the field of pharmaceutical products and health care and in particular in solid oral dosage delivery mechanisms. Specifically, it provides services of development, manufacturing, packaging, transportation, distribution and related services for drugs and nutritional supplements.
Haupt Pharma AG is a development and production "CDMO" contract company, active in the field of pharmaceutical development and manufacturing by contract. Mainly is engaged in the contract "CDMO" production of drugs in solid, semi-solid and liquid forms, and related services.